LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

Nadia Harbeck, Priya Rastogi, J. O’Shaughnessy, Frances Boyle, Javier Cortés, Hope S. Rugo, Matthew P. Goetz, Erika Hamilton, Chiun‐Sheng Huang, Elżbieta Senkus, A. Tryakin, Patrick Neven, Jens Huober, Ran Wei, Valérie André, M. Muñoz, Belén San Antonio, Ashwin Shahir, M. Martín Jiménez, Stephen Johnston